161 related articles for article (PubMed ID: 34978726)
41. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
Lu DP; Dong L; Wu T; Huang XJ; Zhang MJ; Han W; Chen H; Liu DH; Gao ZY; Chen YH; Xu LP; Zhang YC; Ren HY; Li D; Liu KY
Blood; 2006 Apr; 107(8):3065-73. PubMed ID: 16380454
[TBL] [Abstract][Full Text] [Related]
42. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
Dou L; Hou C; Ma C; Li F; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
Ann Hematol; 2020 Jan; 99(1):167-179. PubMed ID: 31828376
[TBL] [Abstract][Full Text] [Related]
43. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
44. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study.
Chang YJ; Wu DP; Lai YR; Liu QF; Sun YQ; Hu J; Hu Y; Zhou JF; Li J; Wang SQ; Li W; Du X; Lin DJ; Ren HY; Chen FP; Li YH; Zhang X; Huang H; Song YP; Jiang M; Hu JD; Liang YM; Wang JB; Xiao Y; Huang XJ
J Clin Oncol; 2020 Oct; 38(29):3367-3376. PubMed ID: 32650683
[TBL] [Abstract][Full Text] [Related]
45. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
[TBL] [Abstract][Full Text] [Related]
46. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
47. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
Messina G; Giaccone L; Festuccia M; Irrera G; Scortechini I; Sorasio R; Gigli F; Passera R; Cavattoni I; Filippi AR; Schianca FC; Pini M; Risitano AM; Selleri C; Levis A; Mordini N; Gallamini A; Pastano R; Casini M; Aglietta M; Montanari M; Console G; Boccadoro M; Ricardi U; Bruno B;
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1600-7. PubMed ID: 22484666
[TBL] [Abstract][Full Text] [Related]
48. Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia.
Remberger M; Mattsson J; Hausenberger D; Schaffer M; Svahn BM; Ringdén O
Eur J Haematol; 2008 May; 80(5):419-28. PubMed ID: 18284619
[TBL] [Abstract][Full Text] [Related]
49. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Kanate AS; Mussetti A; Kharfan-Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A; Chhabra S; Fenske TS; Freytes C; Gale RP; Ganguly S; Hertzberg M; Klyuchnikov E; Lazarus HM; Olsson R; Perales MA; Rezvani A; Riches M; Saad A; Slavin S; Smith SM; Sureda A; Yared J; Ciurea S; Armand P; Salit R; Bolaños-Meade J; Hamadani M
Blood; 2016 Feb; 127(7):938-47. PubMed ID: 26670632
[TBL] [Abstract][Full Text] [Related]
50. Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage.
Zheng C; Tang B; Yao W; Tong J; Zhu X; Song K; Geng L; Liu H; Sun Z
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1708-12. PubMed ID: 24060407
[TBL] [Abstract][Full Text] [Related]
51. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.
Sauter C; Abboud M; Jia X; Heller G; Gonzales AM; Lubin M; Hawke R; Perales MA; van den Brink MR; Giralt S; Papanicolaou G; Scaradavou A; Small TN; Barker JN
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1460-71. PubMed ID: 21310254
[TBL] [Abstract][Full Text] [Related]
52. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
54. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
[TBL] [Abstract][Full Text] [Related]
55. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Koreth J; Stevenson KE; Kim HT; McDonough SM; Bindra B; Armand P; Ho VT; Cutler C; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Alyea EP
J Clin Oncol; 2012 Sep; 30(26):3202-8. PubMed ID: 22869883
[TBL] [Abstract][Full Text] [Related]
56. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation.
Kuriyama K; Fuji S; Inamoto Y; Tajima K; Tanaka T; Inoue Y; Ito R; Hayashi Y; Ito A; Kurosawa S; Kim SW; Yamashita T; Fukuda T
Int J Hematol; 2016 Apr; 103(4):453-60. PubMed ID: 26857285
[TBL] [Abstract][Full Text] [Related]
57. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
Cho BS; Min GJ; Park SS; Yoon SY; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
Am J Hematol; 2021 Nov; 96(11):1441-1449. PubMed ID: 34390504
[TBL] [Abstract][Full Text] [Related]
58. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Baron F; Zachée P; Maertens J; Kerre T; Ory A; Seidel L; Graux C; Lewalle P; Van Gelder M; Theunissen K; Willems E; Emonds MP; De Becker A; Beguin Y
J Hematol Oncol; 2015 Feb; 8():4. PubMed ID: 25652604
[TBL] [Abstract][Full Text] [Related]
59. A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.
Nishida T; Kobayashi T; Sawa M; Masuda S; Shibasaki Y; Goto T; Fukuhara N; Fujii N; Ikegame K; Sugita J; Ikeda T; Kuwatsuka Y; Suzuki R; Najima Y; Doki N; Kato T; Inagaki Y; Utsu Y; Aotsuka N; Masuko M; Terakura S; Onishi Y; Maeda Y; Okada M; Teshima T; Murata M
Ann Hematol; 2021 Mar; 100(3):743-752. PubMed ID: 33427909
[TBL] [Abstract][Full Text] [Related]
60. Disability related to chronic graft -
Fatobene G; Storer BE; Salit RB; Lee SJ; Martin PJ; Cheng GS; Carpenter PA; Balgansuren G; Petersdorf EW; Delaney C; Sandmaier BM; Milano F; Flowers ME
Haematologica; 2019 Apr; 104(4):835-843. PubMed ID: 30442722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
